Ilias A.
- Country
- Greece
- Department
- Oncology Department
Research Overview
- A Phase 3 Randomized Open-Label Study of Sacituzumab Govitecan Versus Physician's Choice in Recurrent or Persistent Endometrial Cancer Post-Chemotherapy and Immunotherapy
- Evaluation of Minimal Residual Disease Monitoring via ctDNA in HR-Positive/HER2-Negative Early Breast Cancer Using Abemaciclib, Inavolisib, and Giredestrant
Data & Insights
Has run more than one trial at 13 of 89 partner sites.
Specializations
Gynecologic Oncology
This investigator specializes in advancing treatments for endometrial cancer, with particular emphasis on developing therapeutic strategies for patients with recurrent or persistent disease conditions.
- Advanced endometrial cancer management
- Recurrent disease treatment approaches
- Post-platinum therapy options
The research focus encompasses evaluating novel therapeutic interventions for patients who have progressed after standard treatments.
Immunotherapy Research
The investigator's work includes studying immunotherapy applications in gynecologic cancers, particularly exploring treatment sequences and combinations in endometrial cancer care.
- Post-immunotherapy treatment strategies
- Sequential therapy approaches
- Innovative treatment combinations
Their research examines therapeutic options for patients who have received prior immunotherapy treatments.
Treatment Assessment
The investigator focuses on evaluating survival outcomes and treatment efficacy in gynecologic oncology, with particular attention to progression-free and overall survival metrics.
- Treatment response evaluation
- Survival outcome assessment
- Comparative treatment efficacy
Their work involves assessing various treatment approaches through independent review methodologies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.